Anti-folate Receptor Alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) Improves T-cell Function Across Physiologically Relevant Ranges of FRα Expression and T-cell Receptor Affinities Post date November 12, 2022 ← ITIL-306-201: A Multicenter, First-in-Human Phase 1a/1b Study of ITIL-306, an Engineered Autologous TIL Cell Therapy Product, in Adults With Advanced Solid Tumors → A CD28/CD40 based chimeric costimulatory antigen receptor (CoStAR™) targeting folate receptor alpha enhances anti-tumour activity of tumour infiltrating lymphocytes
Instil BioInstil Bio